Abstract 511P
Background
Disruption of the immune system is known to favor carcinogenesis and cancer breakthrough. Gliomas constitute de most prevalent primary malignant brain tumors. We aimed to study the occurrence of immune disruptive conditions (IDC) in patients with gliomas at our institution.
Methods
Retrospective study of patients (pts) diagnosed with a glioma at Hospital Clínico Universitario San Carlos, Madrid (Spain). IDCs included autoimmune diseases (AID), organ transplantation (OT) requiring chronic immunosuppressive therapy (IST), and hematological malignancies (HM). A descriptive study, as well as time since IDC, time under IST, and progression-free survival (PFS) and overall survival (OS) since glioma diagnosis were analyzed.
Results
Within the period January 1999 – April 2023, among 481 patients diagnosed with a glioma, 30 (6.2%) patients harbored IDCs. Male/Female: 14/16. Age: 63y (32-83). WHO 5th Ed.: IDH-WT GB: n=26 (MGMTmeth: 50%, MGMTunmeth: 50%), IDH-MUT Astro: n=3, Pleomorphic xanthoastro: n=1. Frontal: n=14, Temporal: n=8, Parietal: n=6. Unilobar: n=23, Bilobar: n=4, Trilobar: n=1. Right: n=8, Left: n=19, Bilateral: n=3. Resection: GTR=8, STR=1, Partial=3, Biopsy=14. RTx=20 pts, CRTx=18, Adj CTx=13. Median PFS and OS since diax were 9 and 10 months (m), respectively. No. of IDCs: 1 (n=21 pts), ≥ 2 (n=9 pts). IDC type: AID (n=27 pts) among which: endocrine (4: Addison, Hypothyroidism, Hashimoto's thyroiditis), respiratory (7: asthma, sarcoidosis, alergic rinoconjunctivitis), cutaneous (7: chronic eccema, psoriasis), neurological (4: multiple sclerosis, Guillain-Barré), digestive system (2: inflammatory bowel disease), rheumatological (13: Horton's disease, Sjöegren's syndrome, systemic lupus erithematosus, uveitis, vasculitis); HM (1: chronic lymphocytic leukaemia); OT (2: renal). IST for IDCs used in 20 pts (systemic IST in 17). Median time since IDC: 101 m (10-411). Median time under IST: 108 m (0-283).
Conclusions
Within a large 24-year long retrospective series, a minority of pts with glioma harbored an IDC, most commonly rheumatological, respiratory, or cutaneous. Studies should be conducted to unveil if gliomas occurring in pts with IDCs are biologically and immunologically distinct.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Cabezas-Camarero: Financial Interests, Personal, Invited Speaker: MSD, Bristol Myers Squibb, Janssen; Non-Financial Interests, Personal, Funding, Research project Head and Neck Cancer: Merck KgGa; Other, Personal, Other, Travel arrangement: Merck KgGa; Other, Personal, Other, Travel arrangements: Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
514P - Immunophenotypic profile of glioblastoma microenvironment: A cohort study
Presenter: Lidia Gatto
Session: Poster session 09
515P - A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
Presenter: Shu Zhou
Session: Poster session 09
516P - Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
Presenter: Kristi Beshiri
Session: Poster session 09
517P - Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning
Presenter: Katherine Hewitt
Session: Poster session 09